{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.13","estimateComment":"Hazard ratio (95% CIs) are based on the treatment effect (Bosutinib compared with Imatinib) in a stratified (by Sokal risk group at randomization and region) Cox proportional hazards model for the hazard of the respective event.","groupDescription":"The medians have not been reached in either arm, as such, the premature estimated hazard ratio is provided.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.39"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.9","upperLimit":"98.9","value":"97.4"},{"groupId":"OG001","lowerLimit":"88.9","upperLimit":"96.5","value":"93.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"description":"The Kaplan-Meier curve was generated based on the first date of CCyR until the date of the confirmed loss of CCyR or censoring, objectively documented, for responders only. Confirmed loss of CCyR was the presence of at least one Ph+ metaphase confirmed by a second assessment at least 28 days later. Treatment discontinuation due to suboptimal response/treatment failure, PD or death due to PD within 28 days of last dose were considered confirmed loss of CCyR. PD was defined as disease progression to AP or BP CML.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"},{"description":"Participants with Philadelphia chromosome-positive CML received imatinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"mITT population included all randomized participants with Ph+ CML harboring the b2a2 and/or b3a2 transcript and baseline BCR-ABL copies \\>0 with study drug assignment designated according to initial randomization and who achieved CCyR (responders). Here, \"N\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Month 48","title":"Kaplan-Meier Estimate of Probability of Retaining Complete Cytogenetic Response (CCyR) at Month 48","type":"SECONDARY","unitOfMeasure":"percentage of participants"}